Vertex Pharmaceuticals Inc
NASDAQ:VRTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
347.04
516.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc
Intangible Assets
Vertex Pharmaceuticals Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$831.6m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$66.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
46%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$20.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$28.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
Glance View
Vertex Pharmaceuticals Inc. is a leading biotechnology company that has carved out a significant niche in the healthcare landscape, primarily focusing on the development of innovative treatments for serious diseases, particularly cystic fibrosis (CF). Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has transformed the lives of patients with CF through its groundbreaking therapies that target the underlying causes of the disease rather than merely addressing symptoms. With a robust pipeline, the company continues to leverage its cutting-edge research capabilities to explore treatments for a range of other diseases, including pain and sickle cell disease, fostering a vision that extends beyond its current portfolio. For investors, Vertex stands out not only for its impressive track record of growth and profitability but also for its strategic partnerships and collaborations that enhance its research potential. The company’s flagship products, including Kalydeco and Trikafta, have seen substantial market success, establishing Vertex as a leader in the cystic fibrosis space. With strong financial performance signals—delivering consistent revenue growth and a commitment to reinvesting in R&D—investors can look forward to additional pipeline advancements, which may further bolster Vertex's market position. As healthcare continues to evolve, Vertex's unwavering focus on developing transformative therapies positions it as a compelling opportunity for those looking to invest in the future of biotechnology.
See Also
What is Vertex Pharmaceuticals Inc's Intangible Assets?
Intangible Assets
831.6m
USD
Based on the financial report for Sep 30, 2024, Vertex Pharmaceuticals Inc's Intangible Assets amounts to 831.6m USD.
What is Vertex Pharmaceuticals Inc's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
28%
Over the last year, the Intangible Assets growth was 38%. The average annual Intangible Assets growth rates for Vertex Pharmaceuticals Inc have been 28% over the past three years .
You don't have any saved screeners yet
